Perrigo Company plc Ordinary Shares (PRGO): Price and Financial Metrics
Perrigo Company plc Ordinary Shares (PRGO)
Today's Latest Price: $42.58 USD
Updated Oct 28 7:00pm
Add PRGO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
PRGO Stock Summary
- PRGO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 501.7 -- higher than 92.95% of US-listed equities with positive expected earnings growth.
- PRGO's went public 28.88 years ago, making it older than 82.12% of listed US stocks we're tracking.
- The volatility of PERRIGO Co plc's share price is greater than that of merely 6.07% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to PRGO, based on their financial statements, market capitalization, and price volatility, are HRC, BDC, CUB, AIMC, and WAB.
- PRGO's SEC filings can be seen here. And to visit PERRIGO Co plc's official web site, go to www.perrigo.com.
PRGO Stock Price Chart Interactive Chart >
PRGO Price/Volume Stats
| Current price | $42.58 | 52-week high | $63.86 |
| Prev. close | $44.03 | 52-week low | $40.01 |
| Day low | $42.36 | Volume | 815,434 |
| Day high | $43.52 | Avg. volume | 1,018,861 |
| 50-day MA | $47.85 | Dividend yield | 2.04% |
| 200-day MA | $52.24 | Market Cap | 5.81B |
Perrigo Company plc Ordinary Shares (PRGO) Company Bio
Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.
PRGO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $42.58 | $27.7 | -38% |
Below please find a table outlining a discounted cash flow forecast for PRGO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that PERRIGO Co plc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of PERRIGO Co plc, consider:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 60. Its equity weight surpasses that of only 21.17% of free cash flow generating stocks in the Healthcare sector.
- Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.07% -- higher than merely 17.15% of stocks in our DCF forecasting set.
- PERRIGO Co plc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 7.32% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -39% |
| 1% | -39% |
| 2% | -38% |
| 3% | -38% |
| 4% | -37% |
| 5% | -36% |
CRL, ENDP, GSK, CMD, and MOH can be thought of as valuation peers to PRGO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...